Synthesis of ceramides and 1-deoxyceramides (WP5194)
Homo sapiens
Synthesis of ceramides and 1-deoxyceramides from serine and alanine, respectively, including the synthesis of complex glycosphingolipids in humans. Multiple more complex sphingolipid synthesis reactions were added to improve pathway versatility. 1-deoxyceramide synthesis shows a lot of similarities with ceramide synthesis but does not come close in terms of documentation, hence this comprehensive figure.
Authors
Quinten Lok and Denise SlenterActivity
Discuss this pathway
Check for ongoing discussions or start your own.
Cited In
Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.
Organisms
Homo sapiensCommunities
Annotations
Pathway Ontology
ceramide signaling pathway sphingolipid biosynthetic pathway lacto-series glycosphingolipid metabolic pathwayCell Type Ontology
animal cellLabel | Type | Compact Identifier | Comment |
---|---|---|---|
alanine | Metabolite | chebi:16449 | |
ceramide | Metabolite | chebi:52639 | |
sphingosine-1-phosphate | Metabolite | chebi:37550 | |
3-ketosphinganine | Metabolite | chebi:17862 | |
Hexadecenal | Metabolite | hmdb:HMDB0060482 | |
serine | Metabolite | chebi:17822 | |
Lc3Cer | Metabolite | hmdb:HMDB0062485 | |
1-O-acyl-ceramide | Metabolite | chebi:133444 | |
Phosphoethanolamine | Metabolite | chebi:17553 | |
GA2 | Metabolite | chebi:36774 | |
CerP(d18:1/16:0) | Metabolite | chebi:72963 | |
ganglioside GM4 | Metabolite | chebi:27499 | |
sulphatide | Metabolite | chebi:18318 | |
Sphinganine | Metabolite | hmdb:HMDB0000269 | |
Sphingosine | Metabolite | hmdb:HMDB0000252 | |
Dihydroceramide | Metabolite | hmdb:HMDB0006752 | |
Galactosylceramide | Metabolite | chebi:18390 | |
lactosylceramide | Metabolite | chebi:134507 | |
globoside Gb3Cer | Metabolite | chebi:88154 | |
S1P | Metabolite | chebi:37550 | |
sphingomyelins | Metabolite | chebi:62490 | |
Palmitoyl-CoA | Metabolite | chebi:15525 | |
Glucosylceramide | Metabolite | chebi:18368 | |
isogloboside iGb3Cer | Metabolite | chebi:140817 | |
1-Deoxyceramide | Metabolite | chebi:52639 | |
1-Deoxy-3-ketosphinganine | Metabolite | chebi:17862 | |
1-deoxysphinganine | Metabolite | chebi:67109 | |
1-Deoxysphingosine | Metabolite | hmdb:HMDB0000252 | |
1-Deoxydihydroceramide | Metabolite | hmdb:HMDB0006752 | |
CERS4 | GeneProduct | ensembl:ENSG00000090661 | |
UGT8 | GeneProduct | ensembl:ENSG00000174607 | |
UGCG | GeneProduct | ensembl:ENSG00000148154 | |
B3GNT5 | GeneProduct | ensembl:ENSG00000176597 | |
KDSR | GeneProduct | ensembl:ENSG00000119537 | |
DGAT1 | GeneProduct | ensembl:ENSG00000185000 | Uncertain, source material did not specify what protein isoform is responsible for this reaction. |
B4GALNT1 | GeneProduct | ensembl:ENSG00000135454 | |
CERK | GeneProduct | ensembl:ENSG00000100422 | |
ASAH1 | GeneProduct | ensembl:ENSG00000104763 | |
A4GALT | GeneProduct | ensembl:ENSG00000128274 | |
CERS1 | GeneProduct | ensembl:ENSG00000223802 | |
A3GALT2 | GeneProduct | ensembl:ENSG00000184389 | |
SGMS2 | GeneProduct | ensembl:ENSG00000164023 | |
CERS2 | GeneProduct | ensembl:ENSG00000143418 | |
SPHK1 | GeneProduct | ensembl:ENSG00000176170 | |
SGMS1 | GeneProduct | ensembl:ENSG00000198964 | |
CERS3 | GeneProduct | ensembl:ENSG00000154227 | |
DES | GeneProduct | ensembl:ENSG00000175084 | |
B4GALT1 | GeneProduct | ensembl:ENSG00000086062 | |
CERS5 | GeneProduct | ensembl:ENSG00000139624 | |
CERS6 | GeneProduct | ensembl:ENSG00000172292 | |
CERS4 | GeneProduct | ensembl:ENSG00000090661 | |
CERS1 | GeneProduct | ensembl:ENSG00000223802 | |
CERS2 | GeneProduct | ensembl:ENSG00000143418 | |
CERS3 | GeneProduct | ensembl:ENSG00000154227 | |
CERS5 | GeneProduct | ensembl:ENSG00000139624 | |
CERS6 | GeneProduct | ensembl:ENSG00000172292 | |
ASAH1 | GeneProduct | ensembl:ENSG00000104763 | |
SPTLC1 | Protein | uniprot:O15269 |
References
- Targeting Glucosylceramide Synthesis in the Treatment of Rare and Common Renal Disease. Shayman JA. Semin Nephrol. 2018 Mar;38(2):183–92. PubMed Europe PMC Scholia
- 1-Deoxyceramides - Key players in lipotoxicity and progression to type 2 diabetes? Sen P, Hyötyläinen T, Orešič M. Acta Physiol (Oxf). 2021 May;232(1):e13635. PubMed Europe PMC Scholia
- Convergence: Lactosylceramide-Centric Signaling Pathways Induce Inflammation, Oxidative Stress, and Other Phenotypic Outcomes. Chatterjee S, Balram A, Li W. Int J Mol Sci. 2021 Feb 12;22(4):1816. PubMed Europe PMC Scholia